FDA Advisory Panel for IceCure’s Prosense Marketing Authorization Receives Overwhelming Public Response from Stakeholders
IceCure ProSense® Cryoablation System: A Game-Changer for Breast Cancer Treatment Exciting News from FDA Advisory Panel Exciting news has emerged from the FDA Advisory Panel regarding the De Novo marketing submission of the IceCure ProSense® Cryoablation System for early-stage low risk breast cancer. Scheduled for November 7, 2024, this panel will provide recommendations and vote…